METHOD OF PREDICTING RISK OF DEVELOPMENT OF ESSENTIAL ARTERIAL HYPERTENSION IN YOUNG MEN WITH HAEMOCOAGULATION DISORDERS Russian patent published in 2015 - IPC A61B5/00 

FIELD: medicine.

SUBSTANCE: method includes determining factors of a risk of essential arterial hypertension (EAH) development in young men with haemocoagulation disorders. For this purpose determined are: X₁ - level of fibrinogen in blood, g/l; X₂ - level of soluble fibrin-monomer complexes in blood, mg/dl; X₃ - level of high-density lipoproteins in blood, mmol/l; X₄ - a complicated course of pregnancy. 1 is given if the pregnancy was without complications, 0 - if the pregnancy was with complications;. X₅ - late gestosis. 1 is given if no gestosis was registered during the pregnancy, 0 - if gestosis was registered during the pregnancy; X₆ - index of AH in a family, with 1 - if in the family there are relatives, suffering from AH, 0 - if in the family there are no relatives, suffering from AH; X₇ - index of thrombosis in the family in relatives, with 1 - if in the family there are relatives, who had thrombosis, 0 - if in the family there are no relatives after thrombosis; X₈ - excessive weight, with 1 - yes, 0 - no; X₉ - type of the left ventricular ejection. 1 is the normal kinetic type, 2 is the hyperkinetic type, 3 is the hypokinetic type; X₁₀ - type of the left ventricle filling, 1 is normal functional, 2 is hyperfunctional, 3 is rigid. After that prognostic coefficients F₁ and F₂ are calculated by formulae F₁=-0.65-0.53×X₁+0.21×X₂+0.81×X₃+0.45×X₄+0.52×X₅-0.63×X₆-0.87×X₇+0.36×X₈-0.21×X₉-0.88×X_10, F₂=-2.74+1.27×X₁-0.69×X₂-0.54×X₃-0.83×X₄-0.38×X₅-0.44×X₆+0.92×X₇-0.58×X₈+0.95×X₉+0.62×X_10. If F₁>F₂, the prediction is favourable, the probability of EAH development is considered to be low. If F₂>F₁, the prediction is unfavourable, the probability of EAH development is high.

EFFECT: method increases the accuracy of predicting the risk of EAH development in young men with haemocoagulation disorders, which makes it possible to start taking preventive measures aimed at the reduction of frequency of thrombosis development in due time.

2 ex